COLUMBIA, S.C. (February 14, 2022) – Ritedose, a 25-year industry veteran in pharmaceutical development and cGMP manufacturing, just launched two new 503B critical care, unit dose syringe products – Rocuronium Bromide Injection 50 mg/5mL and Rocuronium Bromide Injection 100 mg/10mL. Ritedose 503B Outsourcing Facility is a division of Ritedose.
With an anticipated Beyond Use Date (BUD) of 150 days, the single-dose syringes of Rocuronium Bromide can be stored at room temperature and are already diluted, labeled with cautionary statements, color-coded to ASTM drug class standards, and ready to be administered within OR and acute care settings. The standardized concentrations in pre-filled syringes negate the need for in-hospital compounding and help decrease the possibility of sub or supra therapeutic doses for patients. Ritedose is offering Rocuronium Bromide Injection in multiple per/mL concentrations and fill volumes to meet varied clinical patient needs, as well as to provide clinicians choice in what they prescribe.
“We’re pleased to expand our 503B product portfolio for our hospital partners,” said Ritedose President and CEO Jody Chastain. “Our years of successful production methodology and extensive development resources mean we’re able to reliably deliver quality products, so hospitals can avoid disruptions in patient care.”
Founded in 1995 in Columbia, South Carolina, Ritedose is an industry leader in the aseptic manufacturing and liquid packaging of respiratory inhalation products, and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to foster efficient, consistent and safe dosage delivery. The company’s 25-year track record includes the delivery of more than 8 billion doses since 2012 without a single recall, and its current capacity is 2.1+ billion units annually.